In CD8+ cells, the expression levels of PD1 (+), LAG3 (+), or PD1 (+) LAG3 (+) all showed a decreasing trend after treatment compared with untreated DLBCL patients (Figure 3(b)). This evidence concerns the gene LAG3 and diffuse large B-cell lymphoma.